Our Therapeutic Focus
Persica Pharmaceuticals is a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain (vLBP), chronic Low Back Pain (cLBP) associated with Modic type changes. Modic changes are a sign of inflammation, visible on Magnetic Resonance Imaging (MRI) scans at the vertebral endplate adjacent to a degenerate lumbar disc. PP353 is a patented, targeted intradiscal injection delivered directly to the site of disease. It is designed as an alternative to long-term analgesic use, including opioids, and addresses an underlying cause of vLBP rather than just the symptoms.
PP353
PP353 is a patented, targeted intradiscal antibiotic injection that is delivered directly to the site of infection. It is designed to achieve superior antibiotic disc exposure, with a one-off treatment, thereby reducing systemic side-effects, improving patient compliance and antibiotic stewardship.
PP353 is a non-opioid treatment which addresses an underlying cause, rather than just the symptoms, of cLBP.
Targeting a Significant Unmet Need
Vertebrogenic Lumbar Back Pain (cLBP with Modic Type changes) is a common patient subgroup, readily identifiable on MRI, affecting approximately ten million patients in the US and EU. These patients typically suffer moderate to severe persistent pain and disability for more than 6 months, with limited relief from current standard of care, which includes physiotherapy and analgesia such as opioids. Other treatment options provide only limited short-term relief or involve invasive, irreversible nerve ablation, neither of which addresses the suspected underlying cause of the pathology.